Mina Amin1, Kavita Darji2, Daniel J No3, Tina Bhutani4, Jashin J Wu5. 1. School of Medicine , University of California, Riverside , Riverside , CA , USA. 2. School of Medicine , Saint Louis University , St. Louis , MO , USA. 3. School of Medicine , Loma Linda University , Loma Linda , CA , USA. 4. Department of Dermatology , University of California , San Francisco , CA , USA. 5. Department of Dermatology , Kaiser Permanente Los Angeles Medical Center , Los Angeles , CA , USA.
Abstract
Background: The development of biologic agents directed against distinct cytokines and receptors has advanced the therapeutic options available for psoriasis patients. Evidence from preclinical studies suggests that IL-17 may contribute to the pathogenesis of psoriasis. Objective: The objective was to review the safety and efficacy profile for each IL-17 inhibitor by evaluating phase III clinical trial data. Methods: We reviewed the results of phase III clinical trials for the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab. Results: At week 12, the proportion of patients reaching Psoriasis Area and Severity Index (PASI 75) was above 60% for the most efficacious dose of each agent with favorable and comparable safety profiles. The most commonly reported adverse events were nasopharyngitis, headache, and upper respiratory tract infection. Conclusions: The clinical improvement among psoriasis patients on IL-17 inhibitors is similar or superior to the improvement seen with commercially produced biologic agents available accompanied by a favorable short-term safety profile. The results of the phase III trials indicate that IL-17 inhibitors are effective therapeutic options for psoriasis patients.
Background: The development of biologic agents directed against distinct cytokines and receptors has advanced the therapeutic options available for psoriasispatients. Evidence from preclinical studies suggests that IL-17 may contribute to the pathogenesis of psoriasis. Objective: The objective was to review the safety and efficacy profile for each IL-17 inhibitor by evaluating phase III clinical trial data. Methods: We reviewed the results of phase III clinical trials for the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab. Results: At week 12, the proportion of patients reaching Psoriasis Area and Severity Index (PASI 75) was above 60% for the most efficacious dose of each agent with favorable and comparable safety profiles. The most commonly reported adverse events were nasopharyngitis, headache, and upper respiratory tract infection. Conclusions: The clinical improvement among psoriasispatients on IL-17 inhibitors is similar or superior to the improvement seen with commercially produced biologic agents available accompanied by a favorable short-term safety profile. The results of the phase III trials indicate that IL-17 inhibitors are effective therapeutic options for psoriasispatients.
Authors: Natalie A Prow; Thiago D C Hirata; Bing Tang; Thibaut Larcher; Pamela Mukhopadhyay; Tiago Lubiana Alves; Thuy T Le; Joy Gardner; Yee Suan Poo; Eri Nakayama; Viviana P Lutzky; Helder I Nakaya; Andreas Suhrbier Journal: Front Immunol Date: 2019-11-26 Impact factor: 7.561